top stories

UP­DAT­ED: Still held down by clin­i­cal hold, No­var­tis' Zol­gens­ma falls fur­ther be­hind Bio­gen and Roche as FDA asks for a new piv­otal study

4 hours ago
Cell/Gene Tx
Regulatory

Scoop: ARCH’s Bob Nelsen is back­ing an mR­NA up­start that promis­es to up­end the en­tire man­u­fac­tur­ing side of the ...

4 hours ago
Cell/Gene Tx
Manufacturing

As its biotechs hit the pan­dem­ic ex­it, Lon­gi­tude rais­es $585M for new neu­ro, can­cer, ag­ing and or­phan-fo­cused fund

4 hours ago
Venture

News brief­ing: PureTech plans Nas­daq de­but with sec­ondary list­ing; GoodRx prices $725M IPO

32 minutes ago
Protocols

Latest

Most read

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

3 days ago
Pharma

The mi­cro-cap that tapped a mask-skep­tic con­gress­man for their Covid DSMB is ap­ply­ing for an EUA. Their ev­i­dence? 21 ...

45 minutes ago
Regulatory
Coronavirus

PhII Alzheimer's fail­ure deals new blow to Roche, AC Im­mune — but the tau hy­poth­e­sis is far from dead

53 minutes ago
R&D

J&J re­leas­es PhI­II safe­ty blue­print for Covid-19 vac­cine tri­al. How does it stack up to Mod­er­na, Pfiz­er and ...

1 hour ago
Coronavirus

Covid-19 roundup: J&J be­gins piv­otal Phase III tri­al for vac­cine; Con­tro­ver­sial hu­man chal­lenge tri­als to be­gin in ...

2 hours ago
Coronavirus

With $29M in Se­ries A, Boehringer-backed Li­bra looks to tack­le neu­rode­gen­er­a­tion through cel­lu­lar clean­ing

3 hours ago
Venture
Startups
see latest stream
People

Flag­ship's merged biotech Reper­toire nets ex-Pfiz­er CSO An­tho­ny Coyle as R&D chief

Yesterday

UP­DAT­ED: Rocked by cus­toms in­ves­ti­ga­tion, Leg­end's CFO takes over as CEO Frank Zhang placed un­der house ar­rest

2 days ago

A mi­cro-cap with a po­ten­tial­ly promis­ing coro­n­avirus drug en­lists mask-skep­tic con­gress­man for DSMB

5 days ago
Startups

Im­metas Ther­a­peu­tics nabs $11M Se­ries A to nar­row their bis­pe­cif­ic work tar­get­ing in­flam­ma­tion in age-re­lat­ed ...

4 hours ago

Can a mag­net­ic cell ther­a­py re­place corneal trans­plan­ta­tion? As eight-year jour­ney leads to the clin­ic, two broth­ers ...

Yesterday

La­va breaks pro­longed si­lence with an $83M Se­ries C and two I/O pro­grams set for the clin­ic

6 days ago
Deals

UP­DAT­ED: Two wild weeks for Grail end in $8B Il­lu­mi­na buy­out

2 days ago

Roche vaults to the front of the NL­RP3 clin­i­cal race, pay­ing $448M up­front to bag In­fla­zome

2 days ago

Roche looks to ge­net­ic mod­i­fiers for new drug tar­gets, team­ing up with Dutch biotech in $375M deal

2 days ago
IPOs

Zai Lab hauls in $761M from Hong Kong IPO to push Ze­ju­la, more bud­ding can­di­dates in Chi­na — re­port

Yesterday

Three more biotechs look to jump on­to Nas­daq amid IPO boom, in­clud­ing Nor­bert Bischof­berg­er's Kro­nos

2 days ago

Seat­tle-based Athi­ra, aim­ing for tough Alzheimer's and Parkin­son's tar­gets, rais­es $204M for IPO

5 days ago

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News

Premium storiesSee all

Sean Bo­hen's break from bio­phar­ma is over. The ex-As­traZeneca CMO has re­tired his Big Phar­ma jer­sey and is now — ...

6 days ago
People
Bioregnum

Here's a look at every­thing Mer­ck­'s BD group has done in the past 12 years, il­lus­trat­ing why the Seat­tle Ge­net­ics ...

Last week
Deals
R&D

Arie Bellde­grun and David Chang god­fa­ther the $110M launch of a new cell ther­a­py play­er. And this one is al­so ...

Last week
Startups
R&D

Scoop: Gilead’s CAR-T play­er Kite waves good­bye to re­search chief Pe­ter Em­tage as an­oth­er top ex­ec hits the ex­it

Last week
People
Cell/Gene Tx

Don't missSee all

Blue­print plots re­turn to FDA with new Ay­vak­it da­ta in rare con­di­tion — and the an­a­lysts cheer

17 hours ago
R&D

Af­ter bruis­ing re­jec­tion, blue­bird and Bris­tol My­ers Squibb land ide-cel pri­or­i­ty re­view. But will it mat­ter for the ...

Yesterday
R&D
Cell/Gene Tx

Medicx­i's David Grainger and Francesco De Ru­ber­tis pump €200M in­to six com­pa­nies and what they say is a ...

Yesterday
Venture

UP­DAT­ED: #ES­MO20: Eli Lil­ly shows off the da­ta for its Verzenio suc­cess. Was it worth $18 bil­lion?

2 days ago
R&D

Endpoints Standouts

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

5 months ago
People
Special

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

8 months ago
Special
Pharma

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

10 months ago
People
R&D

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

11 months ago

Peer review See all

Sep
18

Vedan­ta Bio­sciences taps Big Phar­ma vet Jef­frey Sil­ber as CMO; Robert Doe­bele leaves be­hind teach­ing post at Col­orado ...

Sep
11

GSK and J&J alum Vi­jay Red­dy to take con­trol of R&D at Tmu­ni­ty; An­drew Hirsch ex­its Agios for CEO job at C4 ...

Sep
4

Scott Ed­mond­son leaves As­traZeneca, starts new chap­ter at Nim­bus; With IPO filed, Taysha pulls to­geth­er an ...

Aug
28

Michael Var­ney comes out of brief Genen­tech 're­tire­men­t' for R&D gig at Eras­ca; Vivek Ra­maswamy's Im­muno­vant re­cruits ...

Aug
21

MD An­der­son­'s Patrick Hwu to helm Mof­fitt Can­cer Cen­ter; Af­ter Rock­well Med­ical ouster, Robert Chioi­ni gets an­oth­er ...

R&D channel feed

Yesterday

#ES­MO20: Push­ing in­to front­line, Mer­ck and Bris­tol My­ers duke it out with new slate of GI can­cer da­ta

Hav­ing worked in par­al­lel for years to move their re­spec­tive PD-1 in­hibitors up to the first-line treat­ment of gas­troin­testi­nal can­cers, Mer­ck and Bris­tol My­ers Squibb fi­nal­ly have the da­ta ...

READ MORE

#ES­MO20: Am­gen team nails down sol­id ear­ly ev­i­dence of AMG 510’s po­ten­tial for NSCLC, un­lock­ing the door to a wave ...

3 days ago

#ES­MO20: Out to beat Tagris­so, J&J touts 100% ORR for EGFR bis­pe­cif­ic/TKI com­bo — fu­el­ing a quick leap to PhI­II

3 days ago
latest in R&D

#ES­MO20: Bris­tol My­ers marks Op­di­vo's sec­ond ad­ju­vant win — eye­ing a stan­dard of care gap

Yesterday
Pharma

#ES­MO20: Seat­tle Ge­net­ics eyes 4th ap­proval with new da­ta in a crowd­ed field

2 days ago

Im­mune Reg­u­la­tion, tak­ing two clin­i­cal pro­grams to 're­set' the im­mune sys­tem, nets $53M+ Se­ries B

2 days ago
Venture

#ES­MO20: 'As good as any PD-1 out there': Re­gen­eron flash­es PD-(L)1 lung can­cer da­ta to ri­val Mer­ck

2 days ago

#ES­MO20: As­traZeneca aims to spur PRO­found shift in prostate can­cer treat­ment with Lyn­parza OS da­ta

2 days ago
Pharma
see latest stories

Pharma channel feed

4 days ago

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

Late in Au­gust, as ne­go­ti­a­tions on a pric­ing deal with Pres­i­dent Trump reached a boil­ing point, PhRMA pres­i­dent Stephen Ubl sent an email up­date to the 34 bio­phar­ma chiefs that sit on his ...

READ MORE

#ES­MO20: As­traZeneca bur­nish­es Tagris­so's ad­ju­vant NSCLC pro­file with 'un­prece­dent­ed' re­duc­tion in brain mets. Can ...

3 days ago
R&D

Seat­tle Ge­net­ic­s' Astel­las-part­nered ADC nails con­fir­ma­to­ry PhI­II in urothe­lial can­cer

5 days ago
R&D
latest in Pharma

A month af­ter los­ing its lead pro­gram, Uni­ty Biotech­nol­o­gy cuts 30% of staff in re­struc­tur­ing

Last week
R&D

Trump ups the stakes with 'grand­dad­dy of them al­l' drug pric­ing ex­ec­u­tive or­der. But he could be run­ning out of time

Last week

Gilead CEO Dan O'­Day's $21B M&A deal to buy Im­munomedics gets some harsh re­views

Last week
Deals

A year out from FDA ap­proval, Ver­tex looks to ex­pand top-sell­ing CF drug to pe­di­atrics

Last week

Phar­ma's bat­tered rep gets a mod­est facelift in the lat­est in­dus­try rat­ings from Gallup — but it's still look­ing pret­ty bad

2 weeks ago
Bioregnum
Coronavirus
see latest stories

Coronavirus channel feed

19 hours ago

Un­der fire, FDA to is­sue stricter guid­ance for Covid-19 vac­cine EUA this week — re­port

The FDA has been in­sist­ing for months that a Covid-19 vac­cine had to be at least 50% ef­fec­tive – a mea­sure of trans­paren­cy meant to shore pub­lic trust in the agency and in a vac­cine that ...

READ MORE

Signs of an 'Oc­to­ber Vac­cine Sur­prise' alarm ca­reer sci­en­tists. HHS con­tin­ues to claim Azar “will de­fer com­plete­ly ...

Yesterday

Covid-19 roundup: CDC ad­vi­so­ry com­mit­tee de­lays pri­or­i­ty dis­tri­b­u­tion vote; EU re­port­ed­ly in­dem­ni­fy­ing vac­cine mak­ers

Yesterday
latest in Coronavirus

A press of­fi­cer de­parts An­tho­ny Fau­ci’s NI­AID af­ter his un­mask­ing as a hard-right Covid mis­in­for­ma­tion troll

Yesterday

Covid-19 roundup: Trump sug­gests Pfiz­er vac­cine could be first ap­proved; VBI Vac­cines inks de­vel­op­ment deal with Cana­da

2 days ago

As­traZeneca pub­lish­es Covid-19 vac­cine PhI­II pro­to­cols in lock­step with Mod­er­na and Pfiz­er. How are they dif­fer­ent?

2 days ago

Pfiz­er match­es Mod­er­na with their full Covid-19 tri­al blue­print — As­traZeneca says it will un­veil its pro­to­col 'short­ly'

5 days ago
R&D

Covid-19 roundup: AlloVir snags IND ap­proval for po­ten­tial T cell ther­a­py; Sanofi and GSK strike 300 mil­lion-dose deal with the EU 

5 days ago
see latest stories